Omeros (OMER) Receives a Hold from Wedbush

By Jason Carr

Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (OMERResearch Report) today and set a price target of $18.00. The company’s shares closed last Monday at $13.20.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -13.2% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Omeros has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, which is an 87.6% upside from current levels. In a report issued on November 4, Needham also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Omeros’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $16.46 million. In comparison, last year the company had a GAAP net loss of $39.47 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.